The first all-oral treatment for *Trypanosoma brucei gambiense* human African trypanosomiasis (g-HAT), co-developed through an innovative public-private partnership between Sanofi and the Drugs for Neglected Diseases initiative (DNDi) has proven to be effective and safe, according to results of clinical trials led by DNDi and numerous partners in DR Congo and Central African Republic, and published in *The Lancet* in October 2017. This new drug joins new diagnostics to round out the elimination toolbox for this fatal disease that is now at a historical low in terms of global disease burden.

**CO-CHAIR**
Victor Kande Betu Kumeso  
*NTD Director, Ministry of Health, Kinshasa, Democratic Republic of the Congo*

Luc Kuykens  
*Senior Vice-President Global Health Programs, Sanofi, Gentilly, France*

**SESSION INTRODUCTION**
Victor Kande Betu Kumeso  
*NTD Director, Ministry of Health, Kinshasa, Democratic Republic of the Congo*

**DISCUSSION FACILITATION**
Luc Kuykens  
*Senior Vice President Global Health Programs, Sanofi, Gentilly, France*

**AN ALTERNATIVE MODEL FOR DRUG DEVELOPMENT: THE STORY OF FEXINIDAZOLE**
Nathalie Strub-Wourgaft  
*Clinical Director, Drugs for Neglected Diseases initiative, Geneva, Switzerland*

**WORKING IN PARTNERSHIP FOR SLEEPING SICKNESS ELIMINATION: USING NEW TECHNOLOGIES**
Erick Mwamba Miaka  
*Director, National HAT Programme, Kinshasa, Democratic Republic of the Congo*

**FINDING EVERY LAST CASE: THE ROLE OF DIAGNOSTICS IN HAT ELIMINATION**
Veerle Lejon  
*Research Director, Institut de Recherche pour le Développement, Montpellier, France*

**ROLL-OUT OF ALL-ORAL TREATMENT: INTRODUCING A DONATION PROGRAM FOR SLEEPING SICKNESS**
Luc Kuykens  
*Senior Vice-President Global Health Programs, Sanofi, Gentilly, France*

**STRIVING TOWARDS HAT ELIMINATION IN SOUTH SUDAN: AN OPERATIONAL PERSPECTIVE**
Laurence Flévaud  
*Operational Centre Barcelona-Athens, Médecins Sans Frontières*

**MONITORING HAT ELIMINATION: PLANS FOR VALIDATION**
Gerardo Priotto  
*Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland*